At the news
? MIXEDIMPACT 7/10 PRESS-RELEASE filed Mar 27, 2026 at 09:00 ET
AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, which secured $80 million in gross proceeds from a $145 million private placement. Concurrently, Anaptys announced a $100 million stock repurchase plan and a lean post-spin-off structure focused on managing royalty assets with minimal operating expenses.
- First Tracks Bio raised $80 million in gross proceeds from the sale of 5,791,478 shares at $13.81 per share in a private placement.
- The spin-off of First Tracks Bio is expected to close on April 20, 2026.
- Anaptys will retain ~$140–145 million in net cash and investments post-spin-off and operate with less than 10 FTEs and under $10M annual operating expenses.
- Anaptys announced a $100 million stock repurchase plan effective after March 31, 2026, expiring December 31, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access